Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Dec
03
Today In Oncology
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Survey Finds Global Embrace of Integrative Cancer Care
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo